Compare Abeona Therapeutics Inc (ABEO) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Cenovus Energy Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while Cenovus Energy Inc trades at $26.65 (market cap $47.02B). The key difference: Cenovus Energy Inc is far larger — about 126× Abeona Therapeutics Inc's market cap, and Cenovus Energy Inc pays a 2.46% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CVE | |
|---|---|---|
Market Cap | $373.32M | $47.02B |
Sector | Health | Energy |
52-Week High | $7.23 | $31.80 |
52-Week Low | $4.17 | $13.96 |
Enterprise Value | $228.22M | $54.90B |
Dividend Yield | — | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Cenovus Energy (CVE) trades at $25.21, up 2.27% with a bearish technical signal. Recent earnings beats and an attractive P/E of 13.78 highlight fundamental strength, while cash flow trends show operational resilience despite negative net flows. The company maintains a solid balance sheet with a debt-to-asset ratio of 13.63% as of 2024.
CVE offers value with low valuation multiples and consistent profitability, but faces headwinds from volatile oil prices and regulatory challenges. Analyst consensus is mixed with 40.74% buy ratings, suggesting cautious optimism for long-term growth amid sector volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
